Is Thymosin alpha-1 with KPV and LL-37 legal in Australia?

A three-peptide immune blend from the clinic end of the market. The component with the largest trial, thymosin alpha-1, was tested in 1,106 adults with sepsis and did not reduce 28 day mortality. LL-37 has two small positive topical wound trials. KPV has no human data. The combination has never been tested and no vial size is canonical.

The pitch is that one peptide organises the immune response, one calms inflammation and one kills microbes while helping tissue repair. Each third has its own evidence, and one of those files contains a large negative trial that rarely appears in the marketing.

Mechanism: Thymosin alpha-1 modulates T lymphocyte function, interleukin-2 signalling and interferon gamma production. LL-37 is a cationic amphipathic antimicrobial peptide with direct antimicrobial and immunomodulatory activity, and can also promote inflammation in some contexts.

Regulatory history: Thymosin alpha-1 is approved in several countries outside the United States and is not FDA approved. LL-37 and KPV are not approved anywhere. The combination has never been evaluated.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Thymosin alpha-1 with KPV and LL-37 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.